Swedish Orphan Biovitrum Q4 2025 Earnings Report

Swedish Orphan Biovitrum EPS Results

• Actual EPS: $0.60
• Consensus EPS: $0.46
• Beat/Miss: Beat by +$0.14
• One Year Ago EPS: N/A

Swedish Orphan Biovitrum Revenue Results

• Actual Revenue: $846.23 million
• Expected Revenue: $879.40 million
• Beat/Miss: Missed by -$33.17 million
• YoY Revenue Growth: N/A

Swedish Orphan Biovitrum Announcement Details

• Quarter: Q4 2025
• Date: 2/5/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) AB, commonly known as Sobi, is a Swedish biopharmaceutical company focused on developing, manufacturing and commercializing therapies for rare diseases. Its principal areas of activity include hematology, immunology and specialty care, with an emphasis on conditions that have limited treatment options and relatively small patient populations.

Sobi’s portfolio includes treatments for hemophilia and other bleeding disorders, such as Elocta, Alprolix and Vonvendi, as well as medicines for immune-mediated and hematologic conditions. Its products also include Doptelet, which is used in certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for selected complement-mediated diseases. The company also develops products independently and commercializes medicines through licensing and collaboration agreements.

The company’s history traces to the combination of Biovitrum and Swedish Orphan International, completed in 2010. Sobi is headquartered in Stockholm and serves patients and healthcare providers through operations and commercial activities across Europe, North America, the Middle East, Asia and other international markets. Its business includes research and development, regulatory support, manufacturing partnerships and the distribution of specialty medicines.